3月20日，长风药业（02652）发布公告，预计2025年收入将在4.1亿元至4.5亿元之间，而2024年收入约为6.08亿元，显示出显著下降。根据国际财务报告准则(IFRS)，2025年股东应占溢利预计在200万元至300万元之间，而2024年则为约2109万元。经调整净利润（非国际财务报告准则指标）预计为3000万元至3500万元，较2024年的约5187万元下降。
公告指出，收入和净利润下降的主要原因包括CF017（吸入用布地奈德混悬液）售价下降、呼吸道感染整体患病率降低、销售及分销网络重组的过渡性影响、研发支出增加及一次性上市开支等因素。尽管面临挑战，公司仍表示整体业务运营正常，并取得了若干创新药申报的进展。同时，公司已进行H股回购，并可能在市场条件允许的情况下进一步回购。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.